Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 7, 2014, Pages

  Angulo, Paul ^a   George, Jacob ^b   Day, Christopher P ^c   Vanni, Ester ^d   Russell, Lee ^b   De la Cruz, Anna C ^a   Liaquat, Hammad ^a   Mezzabotta, Lavinia ^d   Lee, Eun ^a   Bugianesi, Elisabetta ^d  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

ALT; BMI; Cirrhosis; Iron; ROC

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFERRIN; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; COHORT ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ETHNICITY; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; IRON BINDING CAPACITY; IRON OVERLOAD; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PREVALENCE; RACE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE; BIOSTATISTICS; BLOOD; CHEMISTRY; COMPLICATION; EVALUATION STUDY; LIVER CIRRHOSIS; MIDDLE AGED; SERUM;

ADULT; BIOMARKERS; BIOSTATISTICS; COHORT STUDIES; FEMALE; FERRITINS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; SERUM;

EID: 84902537736     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.11.035     Document Type: Article

References (31)

1. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
2. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
3. Bugianesi E., Manzini P., D'Antico S., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004, 39:179-187.
4. Zelber-Sagi S., Nitzan-Kaluski D., Halpern Z., et al. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. JHepatol 2007, 46:700-707.
5. Yoneda M., Nozaki Y., Endo H., et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci 2010, 55:808-814.
6. Sumida Y., Yoneda M., Hyogo H., et al. Asimple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. JGastroenterol 2011, 46:257-268.
7. Manousou P., Kalambokis G., Grillo F., et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011, 31:730-739.
8. Fracanzani A.L., Valenti L., Bugianesi E., et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. JHepatol 2011, 54:1244-1249.
9. Kowdley K.V., Belt P., Wilson L.A., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85. NASH Clinical Research Network.
10. U.S. Department of Health and Human Services Public Health Service. Non-competing continuation progress report (PHS 2590). Available at: http://grants.nih.gov/grants/funding/2590/phs2590.pdf.
11. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostatic model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
12. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. American Heart Association; National Heart, Lung, and Blood Institute.
13. Serum ferritin concentrations for the assessment of ironstatus and iron deficiency in populations. Vitamin and Mineral Nutrition Information System 2011, WHO, World Health Organization, Geneva, (WHO/NMH/NHD/MNM/11.2). Available at:, Accessed October 5, 2013. http://www.who.int/vmnis/indicators/serum_ferritin.pdf.
14. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. NEngl J Med 2005, 352:1769-1778. Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators.
15. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
16. Harrison S.A., Oliver D., Arnold H.L., et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447.
17. Wai C.T., Greenson J.K., Fontana R.J., et al. Asimple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
18. Shah A.G., Lydecker A., Murray K., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1104-1112. Nash Clinical Research Network.
19. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
20. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321. Nonalcoholic Steatohepatitis Clinical Research Network.
21. Brunt E.M., Kleiner D.E., Wilson L.A., et al. NASH Clinical Research Network (CRN): The NAS and the histopathologic diagnosis of NASH: distinct clinicopathologic meanings. Hepatology 2011, 53:810-820.
22. Bozzini C., Girelli D., Olivieri O., et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005, 28:2061-2063.
23. Bell H., Skinningsrud A., Raknerud N., et al. Serum ferritin andtransferrin saturation in patients with chronic alcoholic andnon-alcoholic liver diseases. JIntern Med 1994, 236:315-322.
24. Tung B.Y., Emond M.J., Bronner M.P., et al. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003, 124:318-326.
25. Valenti L., Fracanzani A.L., Bugianesi E., et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010, 138:905-912.
26. Nelson J.E., Wilson L., Brunt E.M., et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011, 53:448-457.
27. Valenti L., Fracanzani A.L., Dongiovanni P., et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007, 102:1251-1258.
28. Facchini F.S., Hua N.W., Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002, 122:931-939.
29. Valenti L., Fracanzani A.L., Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003, 124:866. author reply 866-867.
30. Valenti L., Dongiovanni P., Piperno A., et al. Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 2006, 44:857-864.
31. Adams L.A., House M.J., St.Pierre T.J., et al. The impact ofphlebotomy in non-alcoholic fatty liver disease: interim resultsofa randomized controlled trial. Hepatology 2013, 58(suppl):498A-499A.